Clinical trialsCompany release

Immix reports 89% complete response for CAR-T NXC-201 in AL amyloidosis, targets 2027 BLA

🇺🇸 Immix Biopharma, Inc. (IMMX) · Thu 12 Nov 2026

Interim NEXICART-2 data in relapsed/refractory AL amyloidosis will go to ASH in December, as Immix confirms a mid-2027 FDA filing plan and cash into mid-2028.

Immix Biopharma reported third-quarter 2026 results on 12 November, alongside a corporate update centred on its BCMA-targeted CAR-T therapy NXC-201 for relapsed or refractory AL amyloidosis.

Interim data from the NEXICART-2 study showed an 89% complete response rate among 45 patients. The company said the results will be given as an oral presentation at the American Society of Hematology (ASH) meeting on 14 December. The summary available does not give details on follow-up, safety findings or response criteria, which will matter when the full dataset appears.

Immix plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration in mid-2027. As context, a BLA is the route by which the FDA reviews biological products, including cell therapies, for marketing authorisation in the US.

The company has also appointed new heads of technical operations and regulatory affairs, functions that typically become central as a cell therapy moves towards a filing. Immix reported $340.9 million in cash, which it expects to fund operations into mid-2028.

What it means for your team

  • Regulatory teams should watch the ASH presentation on 14 December for safety, durability and endpoint details behind the 89% complete response figure.
  • A mid-2027 BLA timetable gives an indication of when FDA review of an AL amyloidosis CAR-T could begin.
  • The new technical operations and regulatory affairs leads point to preparation of CMC and filing readiness, key areas for autologous cell therapy submissions.
  • Pharmacovigilance and market-access groups tracking BCMA-directed therapies may want to monitor how this product is positioned in a rare-disease setting.

Company's press release (SEC filing): Immix Biopharma, Inc. ↗

Article written by VigiEye from the official source (Immix Biopharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →